Abstract: The invention concerns compounds of formula (I) wherein W can represent a -(CH¿2?)¿2?-, -(CH¿2?)-C$m(Z)C- or -CH¿2?-CH=CH- group; R¿2? can in particular represent a piperidinyl group, a 1,2,3,6-tetrahydropyridinyl group optionally substituted, a hexahydro-1(H)-azepinyl group, a piperazinyl group optionally substituted or a morphinopolinyl group; R¿3? can represent a -COR¿1? group; A can in particular represent a phenyl group optionally substituted, a heterocycle or a cyclopentyl group and B can in particular represent a pyridyl group, an aminopyrazinyl group, an aminopyridazinyl group, a pyrimidinyl group optionally substituted by an amino group, a piperidinyl group or an aminopyridinyl group optionally substituted on the pyridine by a (C¿1?-C¿4?) alkyl or (C¿1?-C¿4?) alkoxy group, the amino group capable of being optionally substituted by a (C¿1?-C¿4?) alkyl group. The invention also concerns the preparation of said compounds and their therapeutic use.
NIL
| # | Name | Date |
|---|---|---|
| 1 | in-pct-2002-01213-mum-wo international publication report(5-9-2002).pdf | 2018-08-08 |
| 2 | in-pct-2002-01213-mum-power of authority(8-11-2002).pdf | 2018-08-08 |
| 3 | in-pct-2002-01213-mum-form 3(5-9-2002).pdf | 2018-08-08 |
| 4 | in-pct-2002-01213-mum-form 19(2-4-2004).pdf | 2018-08-08 |
| 5 | in-pct-2002-01213-mum-form 1(5-9-2002).pdf | 2018-08-08 |
| 6 | in-pct-2002-01213-mum-description(complete)-(5-9-2002).pdf | 2018-08-08 |
| 7 | in-pct-2002-01213-mum-declaration(5-9-2002).pdf | 2018-08-08 |
| 8 | in-pct-2002-01213-mum-correspondence(ipo)-(11-2-2009).pdf | 2018-08-08 |
| 9 | in-pct-2002-01213-mum-correspondence(29-3-2004).pdf | 2018-08-08 |
| 10 | in-pct-2002-01213-mum-claims(complete)-(5-9-2002).pdf | 2018-08-08 |